Latest From 3SBio Inc.
Private Company Edition: Kymera said it will take up to three programs into the clinic by next year. Also, three new life science funds recently launched, including a Gates Foundation-backed accelerator for COVID-19 treatments, and Cell Medica reemerges as Kuur with new funding for CAR-NKT therapies.
Former Medivation CEO David Hung launched stealthy oncology start-up Nuvation with $275m in series A venture capital, while Tenaya's series B brought in $92m for small molecules as well as cell and gene therapies to treat cardiovascular diseases.
Private Company Edition: BIO comments suggest definitions of personal data expand the scope of foreign investments in biotech companies that must be reviewed by the Committee on Foreign Investment in the United States (CFIUS). Also, NeuroRx’s $95m deal leads recent private financings.
Approval of China's first rituximab biosimilar under new pathway gives developers much-needed boost and an opening to the international market for made-in-China biosimilars helped by favorable regulatory policy changes at home.
- Large Molecule
- Generic Drugs
- Therapeutic Areas
- Infectious & Viral Diseases
- Renal System
- Shenyang Sunshine Pharmaceutical Co. Ltd.
- Parent & Subsidiaries
- 3SBio Inc.
- Senior Management
Jing Lou, PhD, Chmn., Pres. & CEO
Bo Tan, EVP, CFO
Zhenping Zhu, PhD, Pres., R&D & CSO
- Contact Info
Phone: (86) 24 2581 1820
No. 3 A1, Rd. 10
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.